Revelation Biosciences Statistics
Total Valuation
REVB has a market cap or net worth of $1.25 million. The enterprise value is -$5.29 million.
Important Dates
The last earnings date was Friday, November 8, 2024, after market close.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
REVB has 1.64 million shares outstanding. The number of shares has increased by 525.77% in one year.
| Current Share Class | 1.64M |
| Shares Outstanding | 1.64M |
| Shares Change (YoY) | +525.77% |
| Shares Change (QoQ) | +63.89% |
| Owned by Insiders (%) | 0.18% |
| Owned by Institutions (%) | 6.55% |
| Float | 1.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.22 |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.64
| Current Ratio | 1.64 |
| Quick Ratio | 1.61 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -270.02% and return on invested capital (ROIC) is -92.97%.
| Return on Equity (ROE) | -270.02% |
| Return on Assets (ROA) | -50.98% |
| Return on Capital (ROIC) | -92.97% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.72M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.05% in the last 52 weeks. The beta is 0.15, so REVB's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | -96.05% |
| 50-Day Moving Average | 0.84 |
| 200-Day Moving Average | 1.76 |
| Relative Strength Index (RSI) | 40.80 |
| Average Volume (20 Days) | 1,344,062 |
Short Selling Information
The latest short interest is 41,245, so 2.51% of the outstanding shares have been sold short.
| Short Interest | 41,245 |
| Short Previous Month | 22,746 |
| Short % of Shares Out | 2.51% |
| Short % of Float | 2.51% |
| Short Ratio (days to cover) | 0.69 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.55M |
| Pretax Income | -15.90M |
| Net Income | -15.52M |
| EBITDA | -8.52M |
| EBIT | -8.55M |
| Earnings Per Share (EPS) | -$10.93 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 6.54M |
| Total Debt | n/a |
| Net Cash | 6.54M |
| Net Cash Per Share | $3.98 |
| Equity (Book Value) | 2.67M |
| Book Value Per Share | 0.62 |
| Working Capital | 2.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.58 million and capital expenditures -$36,860, giving a free cash flow of -$16.61 million.
| Operating Cash Flow | -16.58M |
| Capital Expenditures | -36,860 |
| Free Cash Flow | -16.61M |
| FCF Per Share | -$10.11 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |